Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "Phase 3 INDIGO Study Updates - Vorasidenib vs. Placebo for Residual or Recurrent Grade 2 Glioma With an IDH1/2 Mutation"
By
Insights from 2023 ASCO® Annual Meeting
FEATURING
Matthias Preusser
By
Insights from 2023 ASCO® Annual Meeting
FEATURING
Matthias Preusser
Comments 0
Login to view comments.
Click here to Login
